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Abstract
This paper distinguishes a rare subset of myeloid dendritic-like cells found in mouse spleen
from conventional (c) dendritic cells (DC) in terms of phenotype, function and gene expres-
sion. These cells are tentatively named “L-DC” since they resemble dendritic-like cells pro-
duced in longterm cultures of spleen. L-DC can be distinguished on the basis of their
unique phenotype as CD11bhiCD11cloMHCII-CD43+Ly6C-Ly6G-Siglec-F- cells. They dem-
onstrate similar ability as cDC to uptake and retain complex antigens like mannan via man-
nose receptors, but much lower ability to endocytose and retain soluble antigen. While L-
DC differ from cDC by their inability to activate CD4+ T cells, they are capable of antigen
cross-presentation for activation of CD8+ T cells, although less effectively so than the cDC
subsets. In terms of gene expression, CD8- cDC and CD8+ cDC are quite distinct from L-
DC. CD8+ cDC are distinguishable from the other two subsets by expression of CD24a,
Clec9a, Xcr1 and Tlr11, while CD8- cDC are distinguished by expression of Ccnd1 and H-
2Eb2. L-DC are distinct from the two cDC subsets through upregulated expression of
Clec4a3, Emr4, Itgam, Csf1r and CD300ld. The L-DC gene profile is quite distinct from that
of cDC, confirming a myeloid cell type with distinct antigen presenting properties.
Introduction
Dendritic cells (DC) play an important role in the immune system by acting as mediators
between the innate and adaptive immune responses. Under steady-state conditions, DC pro-
cess and present self antigen to T cells to maintain self-tolerance and prevent autoimmunity [1,
2]. DC become activated by danger signals and recruit other leukocytes to sites of infection [2].
Those that acquire infectious agents subsequently mount an antigen-specific T cell response
against the pathogen [1, 2]. While several main DC lineages have been identified as profes-
sional antigen presenting cells (APC), increasingly novel APC are being identified in different
tissues, each with specific functional capacity.
Both humans and mice contain multiple subsets of DC, characterized by distinct capacity
for antigen uptake, processing and presentation leading to T cell activation [1, 3]. The DC line-
age is therefore complex with distinct subtypes occupying different tissue locations, each with
unique cell surfacemarker expression, migration potential, function in immunity and response
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to inflammatory states [1]. Conventional DC (cDC) are the main DC type in spleen, and com-
prise two subsets differing in CD8 expression. CD8+ cDC are phenotypically
CD11chiCD11b-CD8+MHCII+ cells, while CD8- cDC differ in expression of CD11b and CD8
as CD11chiCD11b+CD8-MHCII+ cells [4]. These two subsets are different in terms of cytokine
production and capacity to take up antigen for cross-presentation [5]. CD8+ cDC are thought
to maintain tolerance to self-antigens, consistent with their greater ability in cross-presentation
[6, 7]. They are also the predominant source of IL-12, a cytokinewhich induces CD8+ T cell
proliferation [1]. In contrast, CD8- cDC have weaker cross-priming ability [6], but on stimula-
tion with lipopolysaccharide (LPS), migrate from the resting location in marginal zone into T
cell areas where they secrete inflammatory chemokines [6].
Professional antigen presenting cells process and present exogenous antigen as peptides in
association with MHCII molecules as a prelude to activation of CD4+ T cells. However, cDC
and in particular splenic CD8+ cDC, have been shown to have unique ability to process and
cross-present exogenous antigen in association with MHCI molecules leading to activation of
CD8+ T cells [8]. Cross-presentation can occur by two pathways [9]. The cytosolic pathway
involves uptake of exogenous antigen by endosomes with subsequent release of antigen into
the cytoplasm and degradation by proteasomes. Peptides are then transported into the endo-
plasmic reticulum by transporters associated with antigen processing (TAP) [9], loaded on to
MHCI molecules, and then shuttled to the cell membrane. TAP and the MHCI loading com-
plex have been described in phagosomes and endosomes [10, 11], so it is likely that loading of
peptide onto MHCI can occur in the cytoplasm. By the vacuolar pathway, antigen processing
occurs within endosomes containing lysosomes that break antigen down into peptides [9].
Loading of peptide on to MHCI occurs when vesicles carryingMHCI molecules fuse with pep-
tide-rich endosomes. However, it is possible that DC can use both pathways under different
conditions, and there is evidence in the literature which supports this possibility [10].
One limitation of studying the antigen presenting function of DC is the low number of
these cells. One strategy has been to use in vitro culture methods to generate large numbers of
DC for study. The first method generates monocyte-derivedDC (mo-DC) frommonocytes or
myeloid progenitors using a cytokine cocktail comprising granulocytemacrophage colony-
stimulating factor (GM-CSF), tumor necrosis factor (TNF)-α and interleukin (IL)-4 [12, 13].
The secondmethod generates cDC and pDC from bonemarrow-derivedDC precursors under
the influence of FMS-related tyrosine kinase 3 ligand (FLT3-L) [13–15]. Despite the ease of
generating large numbers of cells by these in vitromethods, the DC derived are heterogeneous
and activated, and not reflective of DC in the normal steady-state state [13]. An alternative
strategy for isolation of DC for study is to use mice that constitutively express specific antigen,
so reducing the need to pulse isolated cells with antigen in vitro, a method which leads to loss
of cells with handling and washing. Use of these mice, reduces the number of APC needed to
do experiments, as well as the preparation time required. For example, ACT-mOVA mice con-
stitutively express membrane-boundedOVA under the actin promotor in all cells [16] so that
APC can be directly isolated from spleen for testing antigen presenting function.
Recently we described a myeloid dendritic-like cell, namely L-DC, which is phenotypically
distinct from known cDC and myeloid subsets in spleen [17]. These cells are also distinguish-
able from neutrophils and monocytes by their unique phenotype as CD11cloCD11bhiC-
D8α-MHCII-Ly6C-Ly6G-Siglec-F- cells [17]. These cells are not DC precursors or progenitors,
nor do they arise from cultures supporting their growth with factors like Flt3L which supports
cDC development [18, 19]. Previous studies have confirmed that L-DC are phenotypically very
distinct from precursor DC in spleen [20–22]. They also arise in vitro in stromal co-cultures
seededwith carefully sorted hematopoietic stem cells (HSC) and multipotential progenitors
(MPP) but not from common dendritic progenitors (CDP) or precursor DC [19, 23]. Using
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Ikaros plastic mutant mice which have a defect which affects the self-renewal capacity of HSC,
it was possible to identify the progenitor of L-DC as a self-renewingHSC [23]. Spleen has also
been shown to contain HSC which give rise to L-DCwhen co-cultured above supportive stro-
mal lines derived from spleen [24, 25]. A combination of studies therefore predict a myeloid
dendritic-like cell type in spleen which arises endogenously fromHSC in spleen.
The in vivo L-DC subset resembles a cell type which was previously defined in long-term
stromal spleen cultures, and in co-cultures of hematopoietic progenitors over splenic stroma
[17, 26, 27]. Early studies on in vitro generated L-DC also showed capacity to uptake dead
tumour cells for generation of cytotoxic T cell responses reflecting cross-presenting capacity
[28]. Recent studies on in vitro generated L-DC revealed capacity to take up external antigen
and to activate CD8+ T cells through cross-priming, although cells were unable to activate
CD4+ T cells [27]. Notably, these in vitro grown cells resemble dendritic as well as myeloid
cells, on the basis of phenotype, but have ability to cross-prime CD8+ T cells [17], a property
previously associated with cDC. In this study, a comparative study of the recently defined in
vivo candidate L-DC subset [20] has been undertaken, comparing these cells with the well-
defined cDC subsets in spleen. L-DCwere sorted from spleen for direct comparison with sub-
sets of CD8+ cDC and CD8- cDC using phenotypic, functional and gene profiling
methodology.
Materials and Methods
Animals
Animals were bred under specific pathogen-free conditions in the Biosciences Facility at the
Australian National University (ANU), Canberra, ACT, Australia. Female mice were used at
6–8 weeks of age in all experiments.Mice were housed in a specific pathogen-free facility in
individually ventilated cages using wood shavings as bedding in rooms regulated for light and
ventilation at a constant temperature (19–24°C).Mice were supplied with sterile water and
commercial grade rodent food pellets. Experimentationwas conducted under protocol
#A2013/11 approved by the Animal Experimentation Ethics Committee at ANU. Animals
were euthanased using carbon dioxide asphyxiation to obtain tissues for cell isolation. The fol-
lowing mouse strains were used in experiments describedhere, with number shown in brack-
ets: C57BL/6J (80), C57BL/6.Tg(TcraTcrb)1100Mjb (OT-I TCR-transgenic (tg) (anti-H-2Kb/
OVA257-264) (25), C56BL/6.SJL/J.OT-II.CD45.1 (OT-II TCR-tg (anti-IAb/OVA323-339) mice)
(15) and C57BL/6-Tg(CAG-OVA)916Jen:WehiAnu (Act-mOVA) (115).
Fractionation of cells
Dendritic and myeloid cells were isolated from dissociatedwhole spleen via red blood cell lysis
followed by negative depletion of red blood cells and lymphocytes using magnetic bead separa-
tion and MACS1 technology (Miltenyi Biotec: Auburn, California,USA). T, B and red blood
cell depletion was performed using specific antibody, i.e. 0.25μg biotinylated anti-Thy1.2 anti-
body/108 cells (T cells), 0.25μg biotinylated anti-CD19 antibody/108 cells (B cells) and 0.25μg
biotinylated anti-Ter119 antibody/108 cells (red blood cells) in 1mL fluorescence activated cell
sorting (FACS) buffer (1% FSC, 0.1% sodium azide in Dulbecco'sModified EagleMedium
(DMEM)). Cells were washed and the supernatant discarded. They were then resuspended at
108 cells/mL in MACS labelling buffer (2mM EDTA/0.5% Bovine SerumAlbumin (BSA) in
Phosphate-Buffered Saline (PBS)) and incubated on ice for 25 minutes. Cells were then washed
twice, resuspended in MACS buffer (108 cells/mL), followed by addition of 20μl of anti-biotin
microbeads/108 cells (Miltenyi) for 25 minutes on ice, washed once, and resuspended in 500μl
of MACS labelling buffer prior to running cells through LS columns (Miltenyi) in a SuperMACS
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II SeparationUnit (Miltenyi) to deplete T and B cells. After washing columns thrice, unbound
cells were collected as flow-through cells.
CD8+ T cells were isolated fromOT-I TCR-tg mice specific for ovalbumin (OVA257-264/H-
2Kb). Splenocytes were enriched for CD8+ T cells using MACS1 technology as described
above, but with depletion of DC, granulocytes,myeloid, B cells and CD4+ T cells using specific
antibodies, i.e. 0.25μg biotinylated anti-CD19 antibody/108 cells (B cells), 0.25μg biotinylated
anti-MHCII antibody/108 cells (DC), 0.25μg biotinylated anti-Gr1 antibody/108 cells (granulo-
cytes and myeloid cells) and 0.25μg biotinylated anti-CD4 antibody/108 cells. CD4+ T cells
were prepared in a similar fashion fromOT-II TCR-tg mice specific for ovalbumin (IAb/
OVA323-339), by substituting anti-CD4 antibody with antibody to deplete CD8+ T cells (0.25μg
biotinylated anti-CD8 antibody/108 cells).
Antibody staining
Antibody staining and flow cytometrywere used to analyse cell surfacemarker expression as
describedpreviously [20]. Non-specific antibody binding via Fc receptors was blocked by incu-
bating cells (106) with anti-CD16/32 (FcBlock: Biolegend: San Diego, CA, USA) at 5μg/mL.
Fluorochrome- or biotin-conjugated antibodies specific for CD11c (N418), CD11b (M1/70),
CD8 (53–6.7), CD19 (1D3), CD43 (IBII), Ter119 (Ter119), Thy1.2 (30-H12), Siglec-F (E50-
2440), Ly6C (HK1.4) and Ly6G (1A8) were purchased from Biolegend. Prior to flow cytometry,
propidium iodide (PI: 1 μg/ml) (Sigma-Aldrich: St. Louis,MO, USA) was added to discrimi-
nate live and dead cells. Flow cytometrywas performed on a BD LSRII flow cytometer (Becton
Dickinson: Franklin Lakes, NJ, USA). Data collection involved forward scatter (FSC), side scat-
ter (SSC) and multiple fluorescence channels detecting CFSE, fluorescein isothiocyanate
(FITC), phycoerythrin (PE), PI, pacific blue (PB), Alexa-700, phycoerythrin-cyanine7
(PE-Cy7), allophycocyanin (APC) and allophycocyanin-cyanine 7 (APC-Cy7). BD FACSDiva
Software (BectonDickinson) was used to acquire data. Data analysis involved post-acquisition
gating using FlowJo software (Tree Star: Ashland, OR, USA).
Cell culture
Cells were cultured in Dulbecco’s Modified EagleMedium (DMEM) supplemented with
22.2mMD-glucose, 13μM folic acid, 27μM L-asparagine, 5.5mM L-arganine HCL, 10% heat
inactivated Fetal Calf Serum (FCS) (JRH Biosciences: Lenexa, Kansas, USA), 10mMHepes
(JRH Biosciences), 2mM L-glutamine (JRH Biosciences), 17.1μM streptomycin (JCSMR),
100U penicillin and 50μM 2-mercaptoethanol (BDH Ltd.: Poole, England) per litre of medium.
This is referred to as supplemented DMEM (sDMEM). Cells were maintained in 5% CO2 in air
with 97% humidity at 37°C.
Cell sorting
Cells were stained with fluorochrome-labelled antibodies and subsets identified for sorting as
described in Fig 1. All incubation and washing steps were performed in sodium azide-free
FACS buffer. After a final wash prior to sorting, cells were filtered through a 70μm nylon cell
strainer (BectonDickinson) for removal of cell clumps. Sorted populations were collected in
complete medium (sDMEM) for culture.
Endocytosis assay
The capacity of cells to take up antigen was assessed in in vivo experiments. Ovalbumin conju-
gated to FITC (OVA-FITC) and mannan conjugated to FITC (mannan-FITC) were delivered
Antigen Presenting Cells in Spleen
PLOS ONE | DOI:10.1371/journal.pone.0162358 September 21, 2016 4 / 23
Fig 1. Phenotypic identification of cDC and L-DC in spleen. Representative flow cytometric analysis outlines the method used for delineation
of subsets. This profile is reflective of multiple similar isolations involving individual mice. Splenocytes were prepared by red blood cells lysis
followed by T and B cell depletion. Cells were then stained with antibodies specific for CD11b, CD11c, CD8, Ly6C, Ly6G, CD43 and Siglec-F.
Prior to flow cytometry, cells were stained with propidium iodide (PI, 1μg/ml) to delineate live (PI-) cells. L-DC and myeloid cells were delineated
on the basis of CD11b versus CD11c expression. Myeloid cells were gated as CD11bhiCD11c- cells, and further delineated on the basis of Ly6C
and Ly6G expression to reveal subsets of inflammatory monocytes (Infl mono) as Ly6ChiLy6G- CD43+Siglec-F- cells, neutrophils (Neutro) as
Ly6C+Ly6G+CD43+Siglec-F- and eosinophils (Eosino) as Ly6C+Ly6G-CD43+Siglec-F+ cells. Resident monocytes (Resi mono) were gated as
Ly6C+Ly6G-CD43hi/+Siglec-F- cells, while L-DC were gated as Ly6C-Ly6G-CD43+Siglec-F- cells. Conventional DC (cDC) were initially gated on
the basis of side scatter (SSC) and CD11c expression. CD8+ cDC were gated as CD11b-CD8+Ly6C-Ly6G- cells, while CD8- cDC were gated as
CD11b+CD8-Ly6C-Ly6G- cells. Gates were set based on fluorescence minus one controls, and numbers in gates represent % specific binding.
doi:10.1371/journal.pone.0162358.g001
Antigen Presenting Cells in Spleen
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intravenously (iv) to mice at 1mg/mouse at different times. Mice were sacrificed at the end of
the timed study and their spleens harvested for analysis of cells. Splenocytes were RBC lysed
and enriched via red blood cell, and T and B cell depletion as described above. After depletion,
cells were collected for antibody staining and for flow cytometric analysis to delineate dendritic
and myeloid subsets in spleen and to measure their antigen uptake.
Activation of CD4+ and CD8+ T cells
The T cell activation capacity of DCwas measured by their ability to induce antigen (OVA)-
specific activation and proliferation of (1) CD4+ T cells isolated from anti-OVA specificOT-II
TCR-tg mice, and of (2) CD8+ T cells from anti-OVA specificOT-I TCR-tg mice. Dendritic
and myeloid cell subsets were sorted from spleens of transgenic Act-mOVA mice. Antigen pre-
senting cells from these mice therefore express OVA antigen in the context of MHCI and
MHCII after in vivo uptake and clearance of dead cells. Candidate APC subsets were sorted
into sDMEM as described in Fig 1, and plated in diluting numbers prior to addition of purified
T cells. Some APC were activated via addition of lipopolysaccharide (LPS, 10μg/mL) before
addition of T cells.
T cells were purified from spleens of OT-I or OT-II mice and labeled with 5-(and 6-) car-
boxyfluorescein diacetate succinimidyl ester (CFSE: Molecular Probes: Eugene, Oregon, USA)
in order to measure proliferation of cells following exposure to antigen. Proliferation was quan-
tified flow cytometrically by the dilution of fluorescencewith each cell division. In order to
label T cells with CFSE, enriched cell populations were washed and resuspended at 107cells/mL
in CFSE labelling buffer (PBS/0.1%BSA). CFSE was added at a final concentration of 2.5μM
and vortexed immediately upon addition to ensure uniform cell labelling. Cells were incubated
at 37°C for 10 minutes followed by addition of 5 volumes of cold complete medium and incu-
bation on ice for 5 minutes to quench labelling. Cells were pelleted (4°C, 5 minutes, 300g) and
washed twice with complete medium. CFSE labelled T cells (105) were added to diluting num-
bers of APC in a total volume of 200μL. After 4 days of co-culture, T cells were collected,
stained with antibodies to clearly define the subset, and proliferation determined flow cytome-
trically by quantitation of CFSE staining in defined T cell subsets.
Microarray analysis of gene expression
Splenic dendritic and myeloid subsets were sorted according to the gating procedure described
in Fig 1. RNA was extracted from sorted subsets using an RNeasy mini kit (Qiagen: Clifton
Hill. VIC, Australia) according to the manufacturer’s instructions. RNA was then labelled and
hybridised to Mouse Gene 1.0ST genechips (Affymetrix: Santa Clara, CA, USA) by Dr Kaiman
Peng (Biomolecular Resource Facility, ANU). The procedures used followed the Applause
WT-Amp ST andWT-Amp Plus ST RNA Amplification Systems protocol published on the
website of Nugen Technologies (San Carlos, CA, USA) (http://www.nugeninc.com/nugen/
index.cfm/products/apl/applause-rna-amplification-systems/). Amplification of cDNA was
performedwith the SPIA amplification kit developed by NuGEN Technologies. The cDNA
samples were fragmented and labeled according to the FL-Ovation™ cDNA Biotin Module V2
protocol (NuGEN Technologies), followed by hybridisation onto genechips (Affymetrix),
which were then washed and stained using the fluidics station (Affymetrix) prior to scanning
and analysis using a GeneArray1 Scanner (Affymetrix).
Scanned images of genechips were processed using Partek (St. Louis, Missouri, USA). Data
files were prepared containing probeset numbers, gene descriptions, signal values and p-values
in text file format. Data files were subsequently exported into Excel (Microsoft: Redmond,WA,
USA) for further processing. Cells sorted from two separate experiments were prepared as
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replicates and ANOVA used to do pairwise analysis. Microsoft Excel was used to build a data-
set of gene expression based on signal value and p value, comparing gene expression between
subsets in terms of fold change. Datasets of genes specifically expressed by individual subsets,
and genes common to several subsets, were selected using set criteria of signal value and p
value.
Statistical analysis
Data have been presented as mean ± standard error for sample size n. Where a normal distri-
bution could be assumed, the Students’ t-test was used to determine significance (p 0.05).
For sample size n 5, where a normal distribution cannot be assumed, theWilcoxon Rank
Sum test was used to test significant (p 0.05).
Results
Phenotypic identification of myeloid and DC subsets in spleen
Based on previous identification studies, L-DC can be gated as a
CD11bhiCD11cloLy6C-Ly6G-CD43+Siglec-F- subset (Fig 1) [20], and reflectmyeloid lineage
cells based on high expression of CD11b. Lack of Ly6C, Ly6G and Siglec-F expression delin-
eates L-DC from other known subsets of monocytes, neutrophils and eosinophils.Monocytes
can be delineated into subsets of resident and inflammatorymonocytes. Resident monocytes
were gated as CD11bhiCD11cloLy6CloLy6G-CD43+/hiSiglec-F- cells, while inflammatorymono-
cytes were gated as CD11bhiCD11c-Ly6ChiLy6G-CD43+Siglec-F- cells. Neutrophils were gated
as CD11bhiCD11c-Ly6C+Ly6G+CD43+Siglec-F- cells, while eosinophils are defined as CD43hi-
Siglec-F+ subset of CD11bhiCD11c-Ly6C+Ly6G- cells. Splenic cDC subsets were isolated based
on accumulated flow cytometry data in the literature [1, 3, 9]. The commonly used gating strat-
egy identifies two cDC subsets by their distinctMHCII and CD8 expression. They were there-
fore gated as CD11chiLy6C-Ly6G- cells, and then further delineated as CD8+ cDC and CD8-
cDC on the basis of MHCII expression and differential CD8 expression (Fig 1).
Comparison of the endocytic capacity of L-DC with cDC
Spleen is a lymphoid organ which also contains a red pulp compartment specialised for filter-
ing blood and blood-borne antigens. It is expected therefore that splenic DCwould be readily
able to endocytose antigen. In this study, pinocytosis and receptor-mediated endocytosis of
antigen were investigated for spleen DC subsets described in Fig 1. This involved infusion of
labelled antigens into blood, with subsequent isolation of subsets to measure their uptake of
antigen. When the soluble antigen OVA-FITC was given to mice by intravenous inoculation,
approximately 50% of CD8+ cDC and CD8- cDC demonstrated ability to endocytose and retain
OVA over a 3-hour period, although this diminished to 10–20% after 6 hours (Fig 2A). For
L-DC, ~20% of cells demonstrated ability to take up FITC-OVA, with ~10% of cells still retain-
ing antigen after 6 hours (Fig 2A).
For receptor-mediated endocytosis, different cell types can have a unique combination of
receptors on their cell membrane to aid uptake of antigen in various forms. Mannose receptor-
mediated uptake of antigen by DC has been reported to play a role in cross-presentation for
activation of CD8+ T cells [29, 30]. In order to determine if L-DC endocytose antigen via man-
nose receptors, mannan conjugated to FITC (mannan-FITC) was delivered intravenously to
C57BL/6J mice and uptake monitored over time (Fig 2B). Both CD8+ cDC and CD8- cDC
demonstrated strong ability to take up mannan via mannose receptors. Over 50% of CD8+
cDC took up mannan-FITC and retained it for 6 hours, compared with ~40% of CD8- cDC
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(Fig 2B). L-DC showed similar high ability to take up and retain mannan as did CD8+ cDC
(Fig 2B). Neutrophils, as controls, did not endocytosemannan-FITC in this in vivo assay. In
terms of comparing cells by their in vivo uptake of mannan, it must be remembered that results
reflect both ability of cells for endocytosis as well as accessibility to blood-borne antigen.
Ability of splenic DC subsets to activate CD4+ T cells
Previously it was shown that L-DC produced in vitro in either long-term cultures of spleen or
in stromal co-cultures were unable to activate CD4+ T cells, a result consistent with their
absence of MHCII expression on the cell surface [20, 22, 27]. These results contrasted with
existing evidence that DC and other APC expressedMHCII and readily took up exogenous
antigens for processing and presentation on MHCII for CD4+ T cell activation. CD8- cDC are
commonly known as the main APC for activation of CD4+ T cells [31]. In order to assess the
functional capacity of the in vivo subset, L-DC along with CD8+ cDC and CD8- cDC, were
sorted from spleens of Act-mOVA mice and compared for capacity to induce activation and
proliferation of CD4+ T cells isolated from OT-II TCR-tg mice. Both CD8+ cDC and CD8-
cDC induced proliferation of CD4+ T cells, with CD8- cDC the stronger inducer (Fig 3) [32]].
Fig 2. Comparison of endocytic ability of cDC subsets and L-DC subsets. The ability of cells to endocytose antigen was measured by
uptake of FITC-conjugated ovalbumin (OVA-FITC) and FITC-conjugated mannan (mannan-FITC). C57BL/6J mice were given A)
OVA-FITC (iv; 1mg per mouse), and B) mannan-FITC (iv; 0.5mg per mouse) at 1, 3 and 6 hours prior to euthanasia for spleen collection.
Control mice were given PBS. Splenocytes were prepared by RBC lysis, and enrichment for dendritic and myeloid cells via T, B cell and red
blood cell depletion. Cells were stained with antibodies and sorted to give L-DC, CD8+ cDC and CD8- cDC subsets as shown in Fig 1.
Uptake of antigen was assessed in terms of % FITC staining cells. Data are representative of 2 similar timed experiments.
doi:10.1371/journal.pone.0162358.g002
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Fig 3. Activation of CD4+ T cells by splenic DC. Antigen presenting ability of DC subsets purified from spleens of Act-
mOVA mice was compared. L-DC, CD8+ and CD8- cDC, and neutrophils as a control, were sorted as described in Fig 1
following enrichment of splenocytes by depletion of red blood cells, and T and B lymphocytes using magnetic bead
technology. Diluting numbers of APC were plated following treatment with and without LPS (10 μg/ml) for 2 hours. This was
followed by addition of 105 CFSE-labelled OT-II (TCR-tg) CD4+ T cells, purified from mouse spleen through depletion of B
cells, CD8+ T cells, DC and myeloid cells using magnetic bead protocols. Cells were cultured at T cell:APC ratios of 33:1,
100:1, 300:1 and 1000:1 for 72 hours. CD4+ OT-II T cells were then gated as PI-Thy1.2+Vα2+CD8- cells, and assessed flow
cytometrically for CFSE dilution as an indicator of T cell proliferation. OT-II T cells cultured alone served as controls (con).
Graphs show % proliferating OT-II cells. Three independent replicate experiments were conducted.
doi:10.1371/journal.pone.0162358.g003
Antigen Presenting Cells in Spleen
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Over three separate experiments, L-DC induced no response in line with the control subset of
neutrophils. While addition of LPS gave ~3-fold increased response with CD8- cDC, LPS had
no effect on responses due to either CD8+ cDC, L-DC or neutrophils (Fig 3). This suggested
that only CD8- cDC expressed Toll-like receptor 4 which binds LPS. These results are consis-
tent with the isolated in vivo L-DC subset being functionally distinct from cDC subsets. This
also confirmed similarity between the classified in vivo subset of L-DC (Fig 1) [20] and in vitro
generated L-DC.
Cross-priming ability of DC subsets under normal and inflammatory
states
Cross-presentation is a property which defines DC, although this property has been reported
to be largely restricted to CD8+ cDC [32–35]. The splenic subsets of L-DC, CD8+ cDC and
CD8- cDCwere isolated from ACT-mOVA mice and compared for ability to activate purified
OTI (TCR-tg) CD8+ T cells (Fig 4). The assay was performed in the steady-state and in the
presence of LPS as a potential inflammatory stimulus [36]. Across experiments I and II, shown
graphically in Fig 4(A) and 4(B), both CD8+ cDC and CD8- cDC showed strong ability to
cross-prime CD8+ OT-I T cells. In this model system, CD8- cDCwere marginally stronger acti-
vators than CD8+ cDC. L-DC demonstrated much weaker ability requiring ~30-fold more
L-DC over CD8- cDC to induce an equivalent T cell proliferative response (Fig 4A, 4B and 4C).
Neutrophils which can cross-present antigen only under certain inflammatory conditions [37]
were used as a control in Experiment I showed almost no ability to induce proliferation in
CD8+ T cells in the steady-state or following LPS activation (Fig 4A and 4C).
The ratio of T cell/APC required to induce 50% proliferation of CD8+ T cells was calculated
in order to compare data across replicate experiments (Fig 3C). The collective data show that
isolated CD8- cDC frommACT-OVA mice demonstrate stronger ability to cross-prime than
do CD8+ cDC. This result is contradictory to the literature which compares isolated normal
CD8+ cDC and CD8- cDC following in vitro pulsing with high concentrations of purified anti-
gen [32, 38]. The combined data shows common trends, although some variability was noted
between experiments. CD8- cDC induced 50% maximum proliferation of CD8+ T cells at a
ratio of 900 T cells/APC (Fig 4C). CD8+ cDCwere the second best inducer of CD8+ T cell pro-
liferation, requiring 300 T cells/APC to give half maximum T cell proliferation (Fig 4C). L-DC
were required in higher number, and induced 50%maximum proliferation at ratios of 33 or
100 CD8+ T cells/L-DC (Fig 4C). In addition, the presence of LPS added into co-cultures did
not improve the outcome of T cell activation across replicate experiments for all cell types
tested (Fig 4C). The cross-presenting capacity of purified L-DC is not influenced by the addi-
tion of LPS, even though CD8- cDCwould appear to express the Toll-like Receptor 4 (TLR4)
for LPS, since LPS-activated CD8- cDC induced an increased CD4+ T cell activation response
(Fig 3). This result compares with an earlier study to assess the cross-presenting capacity of a
less pure population of L-DCwhich were isolated, cultured in vitro before pulsing with OVA
as antigen [22]. That study revealed heightened response due to addition of LPS so that cells
produced under those conditions were reflective of cells expressing TLR4 which binds LPS.
The effect of cytochrome c on antigen presentation
Cytochrome c treatment can be used effectively to induce apoptosis specifically in cells with
cross-presenting ability [39]. It is endocytosedby APC in the same way as antigen, and released
into the cytoplasm for cross-presentation via the cytoplasmic pathway. When cytochrome c
enters the cytoplasm after uptake, it binds to apoptotic protease activating factor 1 (Apaf-1) to
form an apoptosome which then induces a caspase cascade resulting in cell death [40]. Uptake
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Fig 4. Cross-presentation ability of DC subsets. Cross-presentation of antigen was investigated for
splenocytes harvested from Act-mOVA mice and prepared by red blood cell lysis and T/B cell depletion.
Splenocyte subsets were stained and gated as described in Fig 1. Diluting numbers of DC were plated as
APC followed by treatment with or without LPS (10 μg/ml) for 2 hours prior to the addition of 105 CFSE-
labelled OT-I (TCR-tg) CD8+ T cells, purified from OT-I mouse spleen through depletion of B cells, CD4+ T
cells, DC and myeloid cells using magnetic bead protocols. A) CD8+ cDC, CD8- cDC, L-DC and neutrophils,
and B) CD8+ cDC, CD8- cDC and L-DC were cocultured with APC in T cell:APC ratios of 33:1, 100:1, 300:1
and 1000:1, respectively. After 72 hours, CD8+ OT-I T cells were gated as PI-CD11b-Thy1.2+Vα2+ cells, and
assessed flow cytometrically for CFSE dilution as an indicator of T cell proliferation. OT-I T cells cultured
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of cytochrome c via endocytosis, and entry into the cytoplasm via cross-presentation, can lead
to cell death [39]. After it was found that cytochrome c selectively killed CD8+ cDC, the mecha-
nism for cross-presentation was thought to involve the cytosolic pathway [39]. L-DCwere
therefore compared with cDC subsets for sensitivity to cytochrome c treatment. Initially, cyto-
chrome c was injected intravenously into mice, and changes in the in vivo representation of all
DC subsets determined in spleen after 6 hours (Fig 5A). However, no difference was found in
the size of the L-DC, CD8+ cDC, or CD8- cDC populations in treated and untreated mice (Stu-
dent’s t test: p 0.01). Further analysis of results for CD8- cDC involved theWilcoxon test
since the variance of the treated and control populations was different. This test again showed
no significant difference at p 0.05. The published in vivo effect of cytochrome c on numbers
of CD8+ cDCwere not reproduced here, although this could be attributed to reported variation
in batches of cytochrome c [39].
Further studies then tested whether cytochrome c treatment had any effect on the cross-pre-
senting capacity of splenic DC subsets measured in vitro. Sorted subsets of DCwere treated
with cytochrome c prior to culture with CFSE-labelledOT-I CD8+ T cells. Consistent with the
literature, a drop in the cross-presenting ability of CD8+ cDCwas observedwhen cells were
treated in vitro with cytochrome c across multiple experiments (Fig 5B). This effect was
reflected by a weaker T cell proliferative response. Similarly, reduced cross-presenting capacity
was observed for CD8- cDC (Fig 5B). Cytochrome c treatment of L-DC did reduce ability to
cross-present antigen to CD8+ T cells in one experiment, but this was not a consistent result,
and gave ~3-fold reduction in only one of four experiments (Fig 5B). In contrast, cytochrome c
treatment resulted in a consistent three-fold increase in the number of CD8- cDC and CD8+
cDC needed to give 50% maximum CD8+ T cell proliferation (Fig 5B). The cross-presenting
capacity of CD8+ cDC and CD8- cDCwas clearly sensitive to cytochrome c treatment, but the
case for L-DCwas less certain, with variable, small effects. One interpretation is that the cyto-
solic pathway for cross-presentation of antigen is used by CD8- cDC and CD8+ cDC, although
it is not used by L-DC. As in Fig 4, neutrophils showed little ability to cross-prime CD8+ T cells
(Fig 5B).
Gene expression distinguishes L-DC from cDC subsets
Gene profiling was conducted to identify potential genes and markers which distinguish L-DC
from the cDC subsets, and to confirm that L-DC is a distinct cell type in vivo. Duplicate sorting
experiments were conducted for mRNA preparation. Microarrays were employed to identify
genes specifically upregulated in L-DC over the two cDC subsets. This involved the preparation
of label frommRNA for hybridisation to AffymetrixGene 1.0ST genechips. ANOVA analysis
was used to make pairwise comparison of original values between subsets. Data were extracted
for genes upregulated at least 3-fold in one subset only amongst the three, using a signal value
of50 to identify absence, but>150 for expression of genes. The number of genes specific to
each dataset was represented in a Venn diagram as a measure of similarity or overlap between
subsets (Fig 6A). Only 24 genes were differentially expressed across each of L-DC, CD8+ cDC
and CD8- cDC subsets (Fig 6A) and these are shown in Fig 6B.
The CD8+ cDC subset was found to be specificallymarked by expression of Xcr1, Ifi205,
Tlr11, Btla, CD24α and Clec9a (Fig 6B). These genes have previously been reported as specific
markers of CD8+ cDC, and reflect their antigen presenting function [33, 41–45]. XCR1 binds
alone served as controls (con). Graphs show % proliferating OT-I cells. C) The T cell/APC ratio required to
generate 50% maximum proliferation of OT-I cells was compared in the presence and absence of LPS
across 5 replicate experiments.
doi:10.1371/journal.pone.0162358.g004
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Fig 5. Effect of cytochrome c treatment on cross-presentation capacity. A) The in vivo killing effect of
cytochrome c on APC was investigated in C57BL/6J mice. Cytochrome c (5mg/mouse) was delivered iv 6
hours prior to euthanasia for spleen collection. Control mice were given PBS. Splenocytes were prepared,
stained and gated as described in Fig 1. Individual mice were analysed. Cell number is presented as %
amongst the total dendritic and myeloid cell population. Mean and standard error (S.E.) are shown by cross
bars. B) The effect of cytochrome c on cross-presentation of antigen was investigated using splenocytes
harvested from Act-mOVA mice and prepared and sorted as described in Fig 1. Diluting numbers of APC
were plated followed by treatment with or without cytochrome c (6 mg/ml) for 2 hours prior to the addition of
105 CFSE-labelled OT-I (TCR-tg) CD8+ T cells, purified from OT-I mouse spleen through depletion of B cells,
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to XCL1 secreted by T cells and aids the migration of DC to T cell areas within spleen, so pro-
moting cross-priming of CD8+ T cells and development of a cytotoxic T cell response [44, 46].
Expression of CLEC9a is restricted to CD8+ cDC and plasmacytoid DC, and plays a specific
role in the uptake of apoptotic cells via binding to the exposed actin filaments of damaged cells
[47, 48]. Recently IFI205 was described as a receptor that regulates signaling via transcriptional
regulation of the inflammasome adapter protein ASC [43]. BTLA has been described as an
inhibitory receptor on DC that regulates T and B cell activation [49]. Genes upregulated by
CD8- cDC included only Ccnd1 andH2-Eb2. CCND1 is involved in cell cycle progression [50],
while H2-Eb2, also known as MHCII, is expressed by APC consistent with the capacity of
CD8- cDC to effectively activate CD4+ T cells [51].
L-DC showed specific upregulation of genes reflecting both myeloid and dendritic lineages
(Fig 6B). Clec4a3, also known as Dcir3, encodes a C-type lectin expressed by DC [52]. Emr4
encodes the epidermal growth factor receptor known to be expressed on CD8- cDC,monocytes
and some macrophages [53]. In addition, L-DC express high levels of Zeb2 and Krt80 involved
in adhesion and migration [54, 55]. L-DC also express myeloid markers like Itgam and Csf1r
[56, 57]. ITGAM, also known as CD11b, is a subunit of the heterodimeric integrinMAC-1,
expressed by myeloid cells which mediates the inflammatory response by regulating adhesion
and migration to sites of infection [58, 59], as well as participating in the phagocytosis of apo-
ptotic cells [60]. Expression of CSF1R is consistent with myeloid lineage cells which respond to
macrophage colony stimulating factor. It was however shown previously that L-DC do not
express CD115 (CSFR1) as a cell surface marker, and are not dependent on CSF1 for their
development in stromal co-cultures in contrast to cDC-like cells [19]. L-DC can also be distin-
guished by upregulated Cd300ld. This gene encodes a type I transmembrane protein with a
CD4+ T cells, DC and myeloid cells using magnetic bead protocols. Cells were cocultured with APC in T cell:
APC ratios of 33:1, 100:1, 300:1 and 1000:1. After 72 hours, CD8+ OT-I T cells were gated as
PI-CD11b-Thy1.2+Vα2+ cells, and assessed flow cytometrically for CFSE dilution as an indicator of
proliferation. OT-I T cells alone served as controls (con). The T cell/APC ratio required to generate 50%
maximum proliferation of OT-I cells was compared in the presence and absence of cytochrome c across 4
replicate experiments.
doi:10.1371/journal.pone.0162358.g005
Fig 6. Differential gene expression. Subsets of CD8+ cDC, CD8- cDC and L-DC were sorted from C57BL/6J mice using the antibody
staining and gating strategy described in Fig 1. RNA was extracted from sorted subsets and converted to cDNA for label preparation, prior
to hybridisation to Murine Gene ST1.0 genechips (Affymetrix). Data were analysed using Partek to give signal values and p values.
ANOVA was employed to determine genes up- and down- regulated 3-fold in pairwise comparison. A) Number of genes
upregulated 3-fold in one of two subsets assessed in pairwise comparison. B) Genes upregulated in only one of three subsets.
doi:10.1371/journal.pone.0162358.g006
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short cytoplasmic tail and a charged transmembrane residue [61]. It is also expressed by granu-
locytes,monocytes,macrophages, monocyte-derivedDC (mo-DC) and pDC, and interacts
with the adaptor chain FcRγ to transmit an activation signal via LYN and SYK kinases [62].
Identification of genes specifically expressed by L-DC
Genes specifically expressed by the L-DC subset but not one or other of the cDC subsets were
then identified in pairwise comparisons selecting genes with a signal value of50 as not
expressed, and those with a signal value150, as expressed. In comparison with CD8+ cDC,
L-DCwere found to specifically express multiple genes related to myeloid cells (Fig 7A; S1 Fig).
L-DC expressed Itgam (CD11b) [22], as well as Klra2, also known as Ly49b, which is expressed
by monocytes,macrophages, NK cells and DC [63, 64]. Ly49B interacts with SHP-1, SHP-2
and SHIP to regulate signaling events [63]. L-DC also specifically expressed the Pilrα, Pilrβ1
and Pilrβ2 genes encoding proteins that regulate SHP signaling (Fig 7A). L-DC also specifically
expressed genes related to macrophages including Emr4, Emr1 and Csf1r (Fig 7A) [65–67], as
well as Nkg7 and GzmaA (Fig 7A), encoding granzymes involved in the induction of apoptosis.
L-DC also specifically expressedmultiple genes related to DC although not CD8+ cDC,
including Clec4a3,Clec4a1,Clec4e,Ace, Fabp4 and CD300ld (Fig 7A). CLEC4 represents a fam-
ily of transmembrane C type lectin receptors involved in diverse functions, including cell adhe-
sion, signaling and inflammation [52]. L-DC expressed 2 isoforms of CLEC4A also described
for CD8- cDC [34, 68]. CLEC4E functions in antigen presentation, and initiation of inflamma-
tory responses after cell death [69, 70]. The expression of CD300LD has been described for
human myeloid lineage DC [71, 72]. L-DC also show expression of FABP4 describedprevi-
ously for human mo-DC, and involved in the production of IL-12 and TNF, as well as T cell
priming [73]. Evidence presented in Fig 7 confirms that specific gene expression in L-DC over
CD8+ cDC reveals that L-DC resemble both dendritic and myeloid lineage cells.
Genes specifically expressed by L-DC but not CD8- cDC included Clec4e, Pilrb2, Fabp4,
Plaur, Dnahc12, Fgd4,Xdh and Smpdl3b, which were also observed in the comparison of L-DC
and CD8+ cDC (Fig 7A and 7B). In addition, L-DC specifically expressedMs4a4a, Zfyve9 and
Lilra5 which were not expressed by CD8- cDC (Fig 7B). LILRA5 expression has been described
for macrophages and induces production of proinflammatory cytokines and IL-10 in a rheu-
matoid arthritis model [74]. ZFYVE9 participates in TGF-β signalling by recruiting and inter-
acting with SMAD2 and SMAD3 proteins [75]. MS4A4A is a novel protein which is also part
of a signaling complex. L-DC specifically expressedmultiple genes involved in signaling path-
ways which distinguish them from CD8- cDC (Fig 7B; S2 Fig). Notably, L-DC did not express
the Zbtb46 gene recently shown to specify cDC development [76].
A final comparison of CD8+ cDC and CD8- cDC also revealedmany genes specific to each
subset. This data is shown in the supplementary data (S3 Fig). In pairwise comparison,multiple
known DC genes were revealed, so validating the experimentation. CD8+ cDC specifically
expressedHepacam2 and Itgae, while CD8- cDC specifically expressed Emr1, Emr4, Clec4a4a,
Clec4a1,Clec4a3,Gm9733,Dscam, Itgam and Apobec1 (S3 Fig). This analysis confirms that the
sorted CD8+ and CD8- cDC subsets were accurately identified and sorted in line with cDC sub-
sets described in the literature.
Discussion
In the past, DC subsets have been identified largely by their cell surface phenotype. However,
this has led to confusion since DC can also express myeloid markers like CD11b and F4/80. A
new nomenclature has been proposed whereby DC,monocytes and macrophages are primarily
classified by their ontogeny and secondarily by their location, function and phenotype [77].
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Fig 7. Specifically expressed genes which identify cDC or L-DC. ANOVA analysis was used to make
pairwise comparison of gene expression between A) CD8+ cDC and L-DC, and B) CD8- cDC and L-DC.
Genes specifically expressed in one of two subsets were selected using the criteria of signal value in one
subset 50, and signal value in the other150. Comparison of CD8+ cDC and L-DC gave a dataset of 139
genes but the complete gene list is shown in supplementary data (S1 Fig). Only genes showing 15-fold
difference in signal value are shown here. Comparison of CD8- cDC and L-DC gave a dataset of 71 genes
which are shown in S2 Fig. Only genes showing 8-fold difference in signal value are shown here.
doi:10.1371/journal.pone.0162358.g007
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Splenic cDC are the best characterisedmurine DC and there have been extensive studies on
their ontogeny, phenotype, function and gene profile [77]. In order to gain a better understand-
ing of L-DC as a distinct in vivo subset, comparison studies were performed here with the CD8+
cDC and CD8- cDC subsets in terms of their function and gene expression. In terms of gene
profile, L-DC are quite distinct and mirror both dendritic and myeloid lineage cells. In terms of
function, L-DC display capacity for receptor-mediated endocytosis of antigen and can activate
CD8+ T cells through cross-presentation, althoughmore weakly than splenic cDC. They do not
however activate CD4+ T cells, whichmakes their classification as a DC less clear. Previously it
was also shown that L-DC are distinguishable from splenic marginal zone and metaphillic mac-
rophages since they do not express either SIGNR1 or MOMA-1 (data not shown).
When gene profiles of L-DCwere compared with those of cDC subsets, L-DCwere found to
upregulate genes encoding both dendritic and myeloid markers (Fig 6B). By comparison with
CD8+ cDC, L-DC specifically expressedmyeloid markers like Emr4, Clec4a3, Emr1, CD300ld,
Csf1r and Itgam (Fig 7A). However, when compared with CD8- cDC, L-DC specifically
expressedmultiple genes involved in signaling pathways clearly distinct from CD8- cDC (Fig
7B). Hence, the L-DC gene profile appears to suggest a myeloid dendritic-like cell distinct from
both CD8- cDC and CD8+ cDC.
The relationship between antigen uptake capacity and cross-presentation capacity has been
studied here using specifically sorted cDC subsets and L-DC characterised in spleen [20]. L-DC
show only receptor-mediated uptake of antigen which is also consistent with their capacity to
cross-present antigen for activation of CD8+ T cells. Inability to pinocytose soluble antigen is
also consistent with their inability to activate CD4+ T cells. There have beenmultiple reports
suggesting that when APC take up antigen, the route of uptake can determine the processing
and presentation pathway used for T cell activation [29, 30, 78]. Burgdorf and coworkers dem-
onstrated that soluble antigen uptake in DC via pinocytosis gives different outcomes in terms of
T cell activation compared with mannose receptor-mediated uptake [29, 30, 78]. They showed
that uptake of antigen via the mannose receptor leads exclusively to activation of CD8+ T cells
as evidence of cross-presentation, while uptake via pinocytosis leads to the activation of CD4+ T
cells. However, their study did not specifically test cDC, since they isolated only CD11c+ spleno-
cytes via density centrifugation and microbead technology, rather than by cell sorting.Here it is
shown that splenic cDC and L-DC have distinct capacities to capture and retain antigen (Fig 2).
CD8+ cDC and CD8- cDC can be distinguished from other DC and myeloid subsets by their
high endocytic ability, their strong cross-priming capacity, and their ability to activate both
CD4+ and CD8+ T cells. In comparison with cDC, L-DC demonstrated strong mannose recep-
tor-mediated uptake of antigen, but weak capacity to endocytose soluble antigen (Fig 2). While
a good activator of CD8+ T cells, L-DC did not activate CD4+ T cells (Fig 3). Previously, a func-
tional mannose receptor was considered to be a marker of cross-presentation ability for splenic
APC subsets [30, 79]. Here, it was found that L-DC have similar capacity for mannose receptor-
mediated uptake as do CD8+ cDC, but a 10-fold lower ability to cross-present antigen (Fig 4C).
Conventional DC are rare cells representing about one percent of spleen leukocytes,while
L-DC are present in even lower frequency [80]. The use of purified subsets of DC in in vitro
assays has been limited by low recovery of cells. To overcome these limitations, ACT-mOVA
transgenic mice were employed as a source of APC [16]. In these mice, cross-presentation of
antigen occurs in vivo, when APC endocytose dead cells and cell debris. However, since the
ACT-mOVA mouse model expresses high levels of cell-associatedOVA protein, it is also pos-
sible that some OVA might enter the endogenous antigen processing pathway. For example,
defective OVA could be tagged for ubiquitin destruction in the cytoplasm, entering protea-
somes, and transported into the endoplasmic reticulum. For this reason, neutrophils, that do
not normally cross-present antigen in wild type mice, were used to assess background levels of
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cross-presentation due to the endogenous pathway in ACT-mOVA mice. Neutrophils from
ACT-mOVA mice, in the absence of LPS stimulation, showed no ability to cross-prime CD8+
T cells, indicating that OVA processing was not occurring via the cytoplasmic pathway in a cell
type which lacks antigen presenting capacity. However, LPS treated neutrophils showed very
weak ability to prime CD8+ T cells, consistent with reports that bonemarrow and peritoneal
neutrophils can prime CD8+ T cells under inflammatory conditions [37].
Using the ACT-mOVA mouse model, and in vitro analysis of function, CD8- cDCwere
found to have the strongest capacity to prime CD8+ T cells, despite having nearly the same abil-
ity to take up antigen via mannose receptors as CD8+ cDC and L-DC (Figs 6 and 7). CD8+
cDC had cross-presenting capacity up to 3-fold weaker than that of CD8- cDC (Figs 2 and 4).
L-DC showed 30-fold weaker capacity to cross prime CD8+ T cells than did CD8- cDC, while
still giving a measurable response (Figs 2 and 4). The hypothesis that antigen uptake via the
mannose receptor is an indicator of cross-presenting ability is not consistent with data pre-
sented here. Others have also questioned that theory, and Segura and coworkers demonstrated
that gene knock-out of aminopeptidase IRAP encoding an enzyme essential for proteolytic
breakdown of antigen in the endosome did not affect the cross-presenting ability of CD8+ cDC
[81]. Similarly, knockdown of mannose receptors in CD8+ cDC did not impact ability to cross-
present antigen [81, 82]. However, gene knockdown of IRAP and mannose receptor did
adversely impact ability of ex vivo isolated monocyte-derivedDC (mo-DC) to cross-prime
[82]. One explanation for these discrepant findings could lie in the purity of DC populations
under study. Another could be that DC have multiple receptors on the cell membrane which
participate in the endocytosis of antigen, also consistent with their ability to clear apoptotic
cells from the environment [83]. Thus, for CD8+ cDC at least, receptors other than the man-
nose receptor might contribute to the uptake of antigens, and these may contribute to cross-
priming of CD8+ T cells in mannose receptor and IRAP knockout mice.
Conclusions
In summary, transcriptome analysis showed clear differences in gene expression between the
splenic subsets of L-DC, CD8+ cDC and CD8- cDC, with L-DC expressing genes indicative of
both dendritic and myeloid cell lineages.While CD8+ cDC and CD8- cDC are similarly strong
activators of CD8+ T cells through cross-presentation, L-DC are relatively weak activators.
Since cross-presentation has been considered a hallmark characteristic of DCwhich distin-
guishes them from other myeloid subsets, L-DCwould appear to reflect a distinct myeloid den-
dritic-like cell.
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